Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study
Journal of Antimicrobial Chemotherapy · 03.01.2025 · 80 (1) · 79-86
DOI: 10.1093/jac/dkae375 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 22.10.2024. Verfasst von Amaury O'Jeanson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Drug Monitoring, beta-Lactamase Inhibitors, beta-Lactams, Anti-Bacterial Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020, Marie Skłodowska-Curie, Swedish Research Council.
Abstract (Originalsprache)
Background
The emergence of β-lactamase-producing bacteria has led to the use of β-lactam (BL) antibiotic and β-lactamase inhibitor (BLI) drug combinations. Despite therapeutic drug monitoring (TDM) being endorsed for BLs, the impact of TDM on BLIs remains unclear.
Objectives
Evaluate whether BLIs are available in effective exposures at the site of infection and assess if TDM of BLIs could be of interest.
Methods
Population pharmacokinetic models for 9 BL and BLI compounds were used to simulate drug concentrations at infection sites following EMA-approved dose regimens, considering plasma protein binding and tissue penetration. Predicted target site concentrations were used for probability of target attainment (PTA) analysis.
Results
Using EUCAST targets, satisfactory (≥90%) PTA was observed for BLs in patients with typical renal clearance (CrCL of 80 mL/min) across various sites of infection. However, results varied for BLIs. Avibactam achieved satisfactory PTA only in plasma, with reduced PTAs in abdomen (78%), lung (73%) and prostate (23%). Similarly, tazobactam resulted in unsatisfactory PTAs in intra-abdominal infections (79%), urinary tract infections (64%) and prostatitis (34%). Imipenem-relebactam and meropenem-vaborbactam achieved overall satisfactory PTAs, except in prostatitis and high-MIC infections for the latter combination.
Conclusions
This study highlights the risk of solely relying on TDM of BLs, as this can indicate acceptable exposures of the BL while the BLI concentration, and consequently the combination, can result in suboptimal performance in terms of bacterial killing. Thus, dose adjustments also based on plasma concentration measurements of BLIs, in particular for avibactam and tazobactam, can be valuable in clinical practice to obtain effective exposures at the target site.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Elisabet I Nielsen, Lena E Friberg
Förderung
- European Union's Horizon 2020
- Marie Skłodowska-Curie
- Swedish Research Council
- European Union’s Horizon 2020
Zitieren
APA
O'Jeanson, A., Nielsen, E. I., & Friberg, L. E. (2025). Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study. Journal of Antimicrobial Chemotherapy, 80(1), 79-86. https://doi.org/10.1093/jac/dkae375
Vancouver
O'Jeanson A, Nielsen EI, Friberg LE. Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study. Journal of Antimicrobial Chemotherapy. 2025;80(1):79-86. doi:10.1093/jac/dkae375
BibTeX
@article{OJeanson2025,
author = {O'Jeanson, Amaury and Nielsen, Elisabet I and Friberg, Lena E},
title = {Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {1},
pages = {79--86},
doi = {10.1093/jac/dkae375}
}
EUVIMED